RecruitingPhase 2NCT06887777
Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (RAVICTI)
Studying Pyruvate dehydrogenase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Intervention
- Glycerol Phenylbutyrate 1100 MG/ML [Ravicti](drug)
- Enrollment
- 15 enrolled
- Eligibility
- 2-25 years · All sexes
- Timeline
- 2025 – 2027
Study locations (1)
- Hôpital Universitaire Necker - Enfants Malades, Paris, France, France
Collaborators
URC-CIC Paris Descartes Necker Cochin
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06887777 on ClinicalTrials.govOther trials for Pyruvate dehydrogenase deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06340685Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) DeficiencyJirair Krikor Bedoyan
- ACTIVE NOT RECRUITINGPHASE3NCT02616484Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:Saol Therapeutics Inc
- RECRUITINGNCT03056794Natural History and Advanced Genetic Study of Pyruvate Dehydrogenase Complex DeficienciesUniversity of Pittsburgh